HIV/AIDS - Extensively drug-resistant Tuberculosis

No registered interventional trials matched to this cause yet.

Extensively drug-resistant tuberculosis (XDR-TB) is curable in some patients, though not in most. Treatment requires prolonged, complex regimens with newer drugs like bedaquiline and linezolid, and can be harsh. Globally, the trajectory is cautiously improving: case detection and treatment access have expanded in recent years, and mortality has been slowly declining, though progress is uneven. The most important milestone is the World Health Organization's 2020 update to consolidated guidelines, which endorsed all-oral bedaquiline-based regimens for drug-resistant TB, replacing older injectable treatments. This shift has improved outcomes and tolerability. Yet capability does not mean universal availability—many high-burden regions still lack access to these effective regimens, and cure rates vary. Research continues, but no major trial breakthroughs are currently registered.

What does 'curable in some' mean for XDR-TB?

It means that with the right treatment—often a combination of newer and older drugs taken for many months—some patients can be cured. But not everyone responds, and the treatment is long and can have side effects. Success depends on the strain, the person's health, and access to quality care.

Is the number of XDR-TB cases going down?

Globally, the overall burden of drug-resistant TB has been slowly declining in recent years, though the trend is not uniform. Better detection and treatment have helped, but in some regions, cases remain high or even rise. Progress is real but fragile.

What was the big change in treatment recently?

The World Health Organization's 2020 guidelines recommended fully oral, bedaquiline-based regimens for drug-resistant TB, replacing older injectable drugs. This has made treatment more effective and easier to tolerate, though access to these newer drugs is still limited in many places.

Are there new drugs or vaccines in development?

Research is ongoing, but no major new treatments or vaccines have been approved recently. Current focus is on improving access to existing drugs like bedaquiline and linezolid, and on optimizing regimens to shorten treatment and reduce side effects. No major trial breakthroughs are currently registered.

Why is XDR-TB so hard to cure?

XDR-TB is resistant to the most powerful first- and second-line drugs, leaving fewer effective options. The remaining drugs are often less potent, more toxic, and must be taken for a long time. Also, the bacteria can hide in the body, making treatment complex and uncertain.